

Progress on capacity expansion is key

Cement ▶ Result Update ▶ **May 3, 2023**

TARGET PRICE (Rs) : 415

In-line quarter

For standalone Jan-Mar 2023 quarter (Q5FY23), Ambuja Cement's (Ambuja) EBITDA stood flat YoY and increased 23% QoQ to Rs7.9bn, in-line with our estimates. EBITDA/ton declined 8% YoY and increased 18% QoQ to Rs977 (Emkay Est.: Rs990). Management has reiterated its key focus areas: i) doubling of capacity from ~68mt to 140mt in five years; ii) Rs300-400/ton improvement in FY24 EBITDA by optimizing manufacturing and logistics cost; and iii) enhancing sales and marketing initiatives to improve the topline. The group is looking to set up 40mt clinker capacity (likely 10 lines of 4mt each); equipment ordering is in advanced stage and is likely to be announced soon in a phased manner, as per management. Consolidated net cash increased Rs1.7bn YoY/Rs21bn QoQ to Rs115bn as of Mar-23. We have broadly maintained our FY24-25 EBITDA estimates. However, factoring in the reduction in ACC's TP, we have revised our Mar-24 TP for Ambuja to Rs415/share (earlier Rs425), based on 15x EV/E.

Ambuja Cements: Financial Snapshot (Standalone)					
Y/E Mar (Rs mn)	CY20	CY21	15MFY23	FY24E	FY25E
Revenue	113,719	139,650	199,854	163,627	175,794
EBITDA	26,466	32,075	32,204	32,662	36,731
Adj. PAT	16,868	21,462	27,108	22,262	25,246
Adj. EPS (Rs)	9.0	10.5	10.3	11.2	12.7
EBITDA margin (%)	23.3	23.0	16.1	20.0	20.9
EBITDA growth (%)	23.2	21.2	(19.7)	26.8	12.5
Adj. EPS growth (%)	17.1	16.2	(1.8)	9.0	13.4
RoE (%)	16.4	21.3	15.9	12.1	12.1
RoIC (%)	39.6	46.6	42.4	30.9	29.5
P/E (x)	34.9	27.0	28.3	26.9	23.4
EV/EBITDA (x)	20.7	18.3	17.5	15.8	13.7
P/B (x)	3.9	3.5	3.4	2.6	2.4
FCFF yield (%)	2.2	1.8	(0.1)	(0.7)	(2.7)

Source: Company, Emkay Research

Results Summary: Cement realization/ton (incl. other operating income) grew 1% YoY/fell ~2% QoQ to Rs5,273. Volumes (incl. clinker) rose 8% YoY and 5% QoQ to 8.1mt (Emkay est.: 7.8mt). Total cost/ton increased by ~3% YoY/declined ~5% QoQ to Rs4,531 vs. our estimate of Rs4,409, owing to lower-than-expected input cost and better operating leverage. Adj. PAT grew 18% YoY/36% QoQ to Rs5.8bn; it has been adjusted for 'exceptional item' of Rs807mn, which pertains to a one-time restructuring cost. Standalone net cash increased by Rs42bn YoY/~Rs18bn QoQ to Rs84bn as of Mar-23.

What we liked: Better-than-expected volume growth and cost initiatives


What we did not like: Lower-than-expected realization and an increase in related-party transactions (RPTs)

Earnings call KTAs: 1) Mgmt. has highlighted its key focus areas - i) Doubling of capacity from ~68mt to 140mt in five years, with the addition of 40mt clinker capacity. Ambuja is looking to set up 10 lines of 4mt each with 90% capacity addition likely through the brownfield route. Mgmt. indicated the entire capex of Rs460bn (over five years) will be funded through internal accruals and any warrants infusion by promoters will be an additional support. ii) Rs300-400/ton improvement in EBITDA for FY24 by optimizing manufacturing and logistics costs. Ambuja is looking to increase WHRS capacity from 70MW to 175MW by Q2FY25; the share of AFR is expected to increase from ~9% to 15% by FY24-end and ~30% in mid-term. Besides, mgmt. is targeting a reduction in lead distance, warehouse optimization and mode mix improvement; iii) Sales and marketing initiatives to focus on 10 high growth states, increase in the share of the B2B segment from 21% to 25% by FY27 and premium products from 22% to ~30%. 2) As per mgmt., outstanding for coal advances stood at Rs14bn, which are likely to be completed in the next few months. 3) RPT reported in ACC/Ambuja is related to the five-year, long-term branding arrangement entered with Adani Sportsline for marketing/sponsorship in several sports leagues (eg. women IPL and Kabaddi league). 4) Mgmt. indicated all upcoming clinker lines will be having adequate limestone reserves. The equipment order is in advanced stage and is likely to be announced soon in a phased-out manner

Target Price - 12M	Mar-24
Change in TP (%)	(2.2)
Current Reco.	HOLD
Previous Reco.	HOLD
Upside/(Downside) (%)	5.3
CMP (28-Apr-23) (Rs)	394.4

Stock Data	Ticker
52-week High (Rs)	598
52-week Low (Rs)	315
Shares outstanding (mn)	1,985.6
Market-cap (Rs bn)	783
Market-cap (USD mn)	9,564
Net-debt, FY24E (Rs mn)	-78,486
ADTV-3M (mn shares)	18
ADTV-3M (Rs mn)	6,639.5
ADTV-3M (USD mn)	81.1
Free float (%)	37-
Nifty-50	18,148
INR/USD	81.9
Shareholding, Mar-23	
Promoters (%)	63.2
FPIs/MFs (%)	11.2/14.7

Price Performance			
(%)	1M	3M	12M
Absolute	7.9	11.9	4.3
Rel. to Nifty	3.2	8.6	(1.7)



Dharmesh Shah
 dharmesh.shah@emkayglobal.com
 +91 22 6612 1255

Exhibit 1: Actual vs Estimates (Q5FY23) Standalone

(Rs mn)	Actual	Estimates		% variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Net sales	42,563	42,189	41,489	0.9	2.6	In-line
EBITDA	7,883	7,735	8,271	1.9	(4.7)	In-line
PAT	5,831	5,003	4,891	16.5	19.2	
Volumes (mt)	8.1	7.8		3.3		
Blended realisation (Rs/ton)	5,273	5,399		(2.3)		
EBITDA (Rs/ton)	977	990		(1.3)		

Source: Company, Bloomberg, Emkay Research

Exhibit 2: Standalone quarterly financials

Rs mn	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q5FY23	YoY (%)	QoQ (%)	FY22	FY23	% YoY
Revenue	39,252	39,935	36,704	41,285	42,563	8.4	3.1	142,688	160,487	12.5
Expenditure	31,348	33,089	33,661	34,892	34,681	10.6	(0.6)	112,477	136,323	21.2
Total RM	5,312	3,217	2,960	7,480	8,695	63.7	16.2	13,471	22,352	65.9
Power & Fuel	10,309	13,198	14,147	12,111	10,343	0.3	(14.6)	37,167	49,799	34.0
Freight	8,682	9,048	8,395	8,362	9,326	7.4	11.5	32,962	35,131	6.6
Staff cost	1,529	1,637	1,532	1,595	1,680	9.8	5.3	6,614	6,444	(2.6)
Other expenditure	5,517	5,989	6,627	5,344	4,637	(15.9)	(13.2)	22,262	22,597	1.5
EBITDA	7,904	6,845	3,043	6,393	7,883	(0.3)	23.3	30,211	24,164	(20.0)
Depreciation	1,515	1,539	1,571	1,648	2,047	35.1	24.2	5,773	6,805	17.9
EBIT	6,389	5,306	1,473	4,745	5,836	(8.7)	23.0	24,438	17,359	(29.0)
Other Income	367	5,878	470	759	1,740	373.9	129.4	2,672	8,846	231.1
Interest	214	251	228	253	335	56.5	32.6	919	1,066	15.9
PBT	6,543	10,933	1,715	5,251	7,241	10.7	37.9	26,191	25,139	(4.0)
Total Tax	1,591	2,398	184	947	1,410	(11.4)	48.8	6,423	4,939	(23.1)
Adjusted PAT	4,952	8,534	1,531	4,303	5,831	17.8	35.5	19,768	20,200	2.2
Extra ordinary items	-	1,945	(152)	(613)	(807)		31.6	(657)	372	(156.6)
Reported PAT	4,952	10,479	1,379	3,690	5,024	1.5	36.2	19,111	20,572	7.6
Adjusted EPS (Rs)	2.5	4.3	0.8	2.2	2.9	17.8	35.5	10.0	10.2	2.2
Margins (%)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q5FY23	YoY (%)	QoQ (%)	FY22	FY23	% YoY
EBIDTA	20.1	17.1	8.3	15.5	18.5	(162)	304	21.2	15.1	(612)
EBIT	16.3	13.3	4.0	11.5	13.7	(257)	222	17.1	10.8	(631)
EBT	16.7	27.4	4.7	12.7	17.0	34	429	18.4	15.7	(269)
PAT	12.6	21.4	4.2	10.4	13.7	108	328	13.9	12.6	(127)
Effective Tax rate	24.3	21.9	10.7	18.0	19.5			24.5	19.6	

Source: Company, Emkay Research; (FY23 includes four quarters for comparative purposes)

Exhibit 3: Standalone quarterly per ton analysis

Rs/ton	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q5FY23	YoY (%)	QoQ (%)	FY22	FY23	% YoY
Cement volumes (mt)	7.5	7.4	7.1	7.7	8.1	7.8	4.8	27.3	30.2	10.8
Blended Realization	5,241	5,404	5,204	5,362	5,273	0.6	(1.7)	5,160	5,259	1.9
Raw Material	709	435	420	971	1,077	51.9	10.9	494	740	49.7
Power & Fuel	1,376	1,786	2,006	1,573	1,281	(6.9)	(18.5)	1,363	1,648	20.9
Freight	1,159	1,224	1,190	1,086	1,155	(0.3)	6.4	1,209	1,163	(3.8)
Staff cost	204	221	217	207	208	1.9	0.5	243	213	(12.1)
Other expenditure	737	810	940	694	574	(22.0)	(17.2)	816	748	(8.4)
Operating cost	4,185	4,478	4,773	4,531	4,296	2.7	(5.2)	4,125	4,512	9.4
EBITDA/ton	1,055	926	432	830	977	(7.5)	17.6	1,108	800	(27.8)

Source: Company, Emkay Research; (FY23 includes four quarters for comparative purposes)

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/03/2023 01:58 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 4: Annual analysis on a per-ton basis

Rs/ton	CY17	CY18	CY19	CY20	CY21	15MFY23	FY24E	FY25E
Blended realisation	4,455	4,525	4,717	4,927	5,103	5,240	5,200	5,325
% YoY	4.9	1.6	4.2	4.5	3.6	2.7	(0.8)	2.4
Raw materials consumed	655	696	755	831	750	1,035	1,000	1,025
Power & fuel costs	970	1,051	1,075	993	1,266	1,595	1,380	1,402
Freight costs	961	1,044	998	950	903	860	850	870
Staff cost	288	281	281	295	251	212	216	218
Other expenses	847	830	846	777	810	744	764	742
Total OpEx	3,721	3,902	3,955	3,847	3,980	4,446	4,210	4,258
% YoY	5.8	4.9	1.3	(2.7)	3.5	11.7	(5.3)	1.1
Other operating income	89	157	131	87	63	61	60	58
Blended EBITDA	824	780	893	1,167	1,187	854	1,050	1,125
% YoY	5.5	(5.3)	14.5	30.7	1.7	(28.0)	22.9	7.1

Source: Company, Emkay Research

Exhibit 5: Maintain HOLD with a TP of Rs415, based on 15x Mar'24E EV/EBITDA


EV/E method	Mar-24E
Mar25E EBITDA	37
Implied EV/E multiple (x)	14.9
EV	549
Net debt (Mar24E)	(83)
Equity value (standalone)	632
ACC- 50% of FV	193
SOTP value	825
No. of shares (mn)	1,986
Mar'24 Target Price (Rs)	415

Source: Company, Emkay Research


Exhibit 6: We broadly maintain our estimates

Earnings revision	CY23E			CY24E		
	Old	New	% chg	Old	New	% chg
Revenue (Rs mn)	164,791	163,627	(0.7)	177,131	175,794	(0.8)
EBITDA (Rs mn)	32,351	32,662	1.0	36,255	36,731	1.3
PAT (Rs mn)	22,603	22,262	(1.5)	24,809	25,246	1.8

Source: Company, Emkay Research

Exhibit 7: 1-year forward EV/EBITDA

Source: Company, Emkay Research

Exhibit 8: 1-year forward EV/Ton

Source: Company, Emkay Research

Ambuja Cements : Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	CY20	CY21	15M15MFY23	FY24E	FY25E
Revenue	113,719	139,650	199,854	163,627	175,794
Revenue growth (%)	(2.5)	22.8	14.5	2.3	7.4
EBITDA	26,466	32,075	32,204	32,662	36,731
EBITDA growth (%)	23.2	21.2	(19.7)	26.8	12.5
Depreciation & Amortization	5,212	5,512	8,324	6,932	7,894
EBIT	21,254	26,562	23,880	25,730	28,837
EBIT growth (%)	32.4	25.0	(28.1)	34.7	12.1
Other operating income	0	0	0	0	0
Other income	3,720	2,856	9,523	5,347	6,256
Financial expense	831	909	1,280	1,196	1,206
PBT	24,144	28,509	32,123	29,881	33,887
Extraordinary items	1,033	(657)	(1,573)	0	0
Taxes	7,276	7,047	5,016	7,620	8,641
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	17,901	20,805	25,535	22,262	25,246
PAT growth (%)	17.1	16.2	(1.8)	9.0	13.4
Adjusted PAT	16,868	21,462	27,108	22,262	25,246
Diluted EPS (Rs)	9.0	10.5	10.3	11.2	12.7
Diluted EPS growth (%)	17.1	16.2	(1.8)	9.0	13.4
DPS (Rs)	18.0	6.3	2.0	2.2	2.5
Dividend payout (%)	199.7	60.1	19.4	20.0	20.0
EBITDA margin (%)	23.3	23.0	16.1	20.0	20.9
EBIT margin (%)	18.7	19.0	11.9	15.7	16.4
Effective tax rate (%)	30.1	24.7	15.6	25.5	25.5
NOPLAT (pre-IndAS)	14,849	19,997	20,152	19,169	21,484
Shares outstanding (mn)	1,985.7	1,985.7	1,985.5	1,985.5	1,985.5

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	CY20	CY21	15MFY23	FY24E	FY25E
PBT	24,144	28,509	32,123	29,881	33,887
Others (non-cash items)	3,924	4,397	-827	2,835	2,901
Taxes paid	-4,648	-3,629	-3,346	-7,620	-8,641
Change in NWC	3,676	-4,615	-7,855	3,244	-953
Operating cash flow	27,095	24,663	20,096	28,341	27,193
Capital expenditure	-9,778	-11,425	-21,116	-33,284	-46,972
Acquisition of business	3,133	-50	-336	-0	0
Interest & dividend income	3,481	2,415	7,724	5,347	6,256
Investing cash flow	-3,164	-9,060	-13,727	-27,936	-40,716
Equity raised/(repaid)	-	-	50,000	-	-
Debt raised/(repaid)	-62	35	5	-	-
Payment of lease liabilities	-	-	-	-	-
Interest paid	-896	-1,183	-679	-1,196	-1,206
Dividend paid (incl tax)	-36,646	-2,021	-12,514	-4,452	-5,049
Others	-	-	-697	-	-
Financing cash flow	-37,604	-3,168	36,115	-5,649	-6,255
Net chg in Cash	-13,674	12,435	42,484	-5,244	-19,778
OCF	26,062	24,663	20,096	28,341	27,193
Adj. OCF (w/o NWC chg.)	22,386	29,278	27,951	25,097	28,146
FCFF	16,284	13,238	(1,019)	(4,943)	(19,779)
FCFE	16,222	13,273	(1,015)	(4,943)	(19,779)
OCF/EBITDA (%)	98.5	76.9	62.4	86.8	74.0
FCFE/PAT (%)	96.2	61.8	(3.7)	(22.2)	(78.3)
FCFF/NOPLAT (%)	109.7	66.2	(5.1)	(25.8)	(92.1)

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	CY20	CY21	15MFY23	FY24E	FY25E
Share capital	3,971	3,971	3,971	3,971	3,971
Reserves & Surplus	199,187	218,101	281,084	298,893	319,090
Net worth	203,159	222,073	285,055	302,864	323,061
Minority interests	0	0	0	0	0
Deferred tax liability (net)	1,860	2,018	2,181	2,236	2,291
Total debt	436	435	477	477	477
Total liabilities & equity	205,454	224,526	287,713	305,577	325,829
Net tangible fixed assets	53,829	71,283	75,562	73,937	105,228
Net intangible assets	1,746	1,742	2,393	2,393	2,393
Net ROU assets	3,740	3,433	8,240	8,240	8,240
Capital WIP	18,737	9,513	8,419	36,396	44,183
Goodwill	0	0	0	0	0
Investments [JV/Associates]	117,877	117,877	117,667	117,667	117,667
Cash & equivalents	29,288	41,723	84,207	78,963	59,185
Current assets (ex-cash)	29,596	36,164	62,552	59,191	61,682
Current Liab. & Prov.	49,360	57,209	71,327	71,210	72,748
NWC (ex-cash)	(19,764)	(21,045)	(8,775)	(12,019)	(11,066)
Total assets	205,454	224,526	287,713	305,577	325,829
Net debt	(28,852)	(41,288)	(83,730)	(78,486)	(58,708)
Capital employed	205,454	224,526	287,713	305,577	325,829
Invested capital	39,551	55,413	77,420	72,551	104,795
BVPS (Rs)	102.3	111.8	114.9	152.5	162.7
Net Debt/Equity (x)	(0.1)	(0.2)	(0.3)	(0.3)	(0.2)
Net Debt/EBITDA (x)	(1.1)	(1.3)	(2.6)	(2.4)	(1.6)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
RoCE (%)	11.6	13.7	10.4	10.5	11.1

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	CY20	CY21	15MFY23	FY24E	FY25E
P/E (x)	34.9	27.0	28.3	26.9	23.4
P/CE(x)	35.5	29.0	27.6	26.8	23.6
P/B (x)	3.9	3.5	3.4	2.6	2.4
EV/Sales (x)	6.7	5.4	3.5	4.4	4.2
EV/EBITDA (x)	20.7	18.3	17.5	15.8	13.7
EV/EBIT(x)	35.5	27.9	36.6	27.4	25.1
EV/IC (x)	19.1	13.4	9.0	9.7	6.9
FCFF yield (%)	2.2	1.8	(0.1)	(0.7)	(2.7)
FCFE yield (%)	2.2	1.8	(0.1)	(0.7)	(2.7)
Dividend yield (%)	4.6	1.6	0.5	0.6	0.6
DuPont-RoE split					
Net profit margin (%)	14.8	15.4	13.6	13.6	14.4
Total asset turnover (x)	0.5	0.6	0.6	0.6	0.6
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	7.9	10.1	8.6	7.6	8.1
DuPont-RoIC					
NOPLAT margin (%)	13.1	14.3	10.1	11.7	12.2
IC turnover (x)	2.6	2.9	3.0	2.2	2.0
RoIC (%)	33.7	42.1	24.3	25.6	24.2
Operating metrics					
Core NWC days	(63.4)	(55.0)	(20.0)	(26.8)	(23.0)
Total NWC days	(63.4)	(55.0)	(20.0)	(26.8)	(23.0)
Fixed asset turnover	1.4	1.4	1.4	1.3	1.2
Opex-to-revenue (%)	60.1	62.5	64.4	61.0	60.1


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	CMP (Rs)	TP (Rs)	Rating	Analyst
27-Mar-23	370	425	Hold	Dharmesh Shah
02-Mar-23	371	425	Hold	Dharmesh Shah
09-Feb-23	358	425	Hold	Dharmesh Shah
05-Feb-23	374	480	Hold	Dharmesh Shah
29-Dec-22	523	480	Hold	Dharmesh Shah
05-Dec-22	573	480	Hold	Dharmesh Shah
05-Nov-22	559	480	Hold	Dharmesh Shah
21-Oct-22	513	480	Hold	Dharmesh Shah
04-Oct-22	492	530	Hold	Dharmesh Shah
19-Sep-22	565	530	Hold	Dharmesh Shah
04-Sep-22	416	360	Hold	Dharmesh Shah
20-Jul-22	368	360	Hold	Dharmesh Shah
04-Jul-22	369	360	Hold	Dharmesh Shah
28-Jun-22	366	360	Hold	Dharmesh Shah
16-May-22	368	410	Hold	Dharmesh Shah
28-Apr-22	383	410	Hold	Dharmesh Shah
16-Mar-22	309	370	Buy	Dharmesh Shah
19-Feb-22	338	400	Buy	Dharmesh Shah
31-Dec-21	378	450	Buy	Dharmesh Shah
19-Dec-21	369	450	Buy	Dharmesh Shah
02-Dec-21	377	450	Buy	Dharmesh Shah
27-Oct-21	382	450	Buy	Dharmesh Shah
05-Sep-21	437	445	Buy	Dharmesh Shah
25-Jul-21	402	445	Buy	Dharmesh Shah
06-Jun-21	332	350	Buy	Dharmesh Shah
30-Apr-21	309	350	Buy	Dharmesh Shah
28-Apr-21	309	350	Buy	Dharmesh Shah

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 3, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of May 3, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 3, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.